Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ebewe pharma - etopozid - koncentrat za raztopino za infundiranje - etopozid 20 mg / 1 ml - etopozid

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ebewe pharma - etopozid - koncentrat za raztopino za infundiranje - etopozid 20 mg / 1 ml - etopozid

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pharmachemie b.v. - etopozid - koncentrat za raztopino za infundiranje - etopozid 20 mg / 1 ml - etopozid

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

teva b.v. - etopozid - koncentrat za raztopino za infundiranje - etopozid 20 mg / 1 ml - etopozid

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lenis d.o.o. - etopozid - koncentrat za raztopino za infundiranje - etopozid 20 mg / 1 ml - etopozid

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

kemofarmacija d.d. - etopozid - prašek za raztopino za injiciranje - etopozid 100 mg / 1 viala - etopozid

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lenis d.o.o. - etopozid - prašek za raztopino za injiciranje - etopozid 100 mg / 1 viala - etopozid

Evropska unija - slovenščina - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastična sredstva - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq kot monotherapy je indiciran za zdravljenje odraslih bolnikov z lokalno napredno ali metastatskim nsclc po predhodno kemoterapijo. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq kot monotherapy je indiciran za zdravljenje odraslih bolnikov z lokalno napredno ali metastatskim nsclc po predhodno kemoterapijo. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Evropska unija - slovenščina - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - drugi antineoplastiki - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

fresenius kabi austria gmbh. - gemcitabin - koncentrat za raztopino za infundiranje - gemcitabin 38 mg / 1 ml - gemcitabin